Intra-lesional radiation boost for bulky cervical cancer
Official title: A Prospective Phase 2 Clinical Trial of Intra-lesional Cervical Tumor Boost for Bulky Cervical Cancer
Run by Seoul National University Bundang Hospital · NCT07435376 · Data updated 2026-11-12
This phase 2 trial tests whether adding an intra-lesional radiation boost to standard pelvic chemoradiation helps shrink large cervical tumors more before brachytherapy and what side effects patients experience.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years to 80 Years |
| Sex | Women only |
| Enrollment | 17 (estimated) |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Status | Recruiting |
| Started | February 23, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | November 30, 2028 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07435376 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 19–80 with histologically confirmed squamous cell carcinoma of the cervix and a bulky primary tumor (≥60 cc or ≥6 cm), an ECOG performance status of 0–2, and who are fit for definitive concurrent chemoradiotherapy and able to give informed consent.
✕Probably not a fit
Patients who may not receive benefit include those with small tumors, non‑squamous histology, prior pelvic radiation or prior neoadjuvant chemotherapy, recent other malignancies, or who are medically unfit or unable to provide informed consent.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with bulky squamous cell carcinoma of the cervix receive pelvic external-beam radiotherapy with a targeted intra-lesional boost using IMRT over about 5–6 weeks, typically with concurrent chemotherapy. Tumor size is measured by MRI during week 4 or 5 to determine whether the boost increases shrinkage prior to standard high-dose-rate brachytherapy. Investigators will record treatment-related side effects and monitor safety throughout and after therapy. This is a single-center phase 2 trial conducted at Seoul National University Bundang Hospital enrolling patients who meet the bulky-tumor and fitness criteria.
Why it matters
Potential benefit: If successful, the boost could increase tumor shrinkage before brachytherapy, improving local control and potentially reducing recurrence or the need for more aggressive treatments.
How similar studies have gone: Dose-escalation and simultaneous integrated boost approaches in cervical cancer have shown promising results in phase II and retrospective reports for improved local control, but intra-lesional boosting in this exact setting remains under active investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically confirmed squamous cell carcinoma of the cervix. * Patients with bulky primary tumor, defined as a tumor volume ≥ 60 cc OR a maximum diameter ≥ 6 cm. * Patients aged 19 to 80 years at the time of diagnosis. * Patients with an ECOG performance status of 0 to 2. * Patients who have voluntarily agreed to participate in the study. Exclusion Criteria: * Diagnosis of other malignancies within 5 years prior to enrollment (Exceptions: carcinoma in situ of the breast and thyroid cancer). * Patients who are medically unfit for definitive concurrent chemoradiotherapy. * Patients who have received prior chemotherapy (neoadjuvant chemotherapy) before radiation therapy. * Patients with prior history of radiation therapy to the abdomen or pelvis. * Patients unable to provide informed consent due to mental or physical disabilities.
Where it's running
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea Recruiting
Study contacts
- Study coordinator: Keun-Yong Eom, MD, PhD
- Email: 978sarang@snubh.org
- Phone: 82-31-787-7653
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.